Drug Type Monoclonal antibody |
Synonyms hOKT3-gamma-1-ala-ala, hOKT3-γ1-ala-ala, Teplizumab (USAN/INN) + [9] |
Target |
Action inhibitors |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (17 Nov 2022), |
RegulationPriority Review (United States), Breakthrough Therapy (United States), Orphan Drug (United States), PRIME (European Union), Priority Review (China), Commissioner's National Priority Voucher (United States) |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D09013 | Teplizumab |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Diabetes Mellitus, Type 1 | United States | 17 Nov 2022 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glucose Intolerance | Phase 2 | United States | 01 Aug 2010 | |
| Glucose Intolerance | Phase 2 | Canada | 01 Aug 2010 | |
| Glucose Intolerance | Phase 2 | Germany | 01 Aug 2010 | |
| Chronic large plaque psoriasis | Phase 2 | United States | 01 Dec 2009 | |
| Chronic large plaque psoriasis | Phase 2 | United States | 01 Dec 2009 | |
| Psoriasis | Phase 2 | United States | 01 Dec 2009 | |
| Psoriasis | Phase 2 | United States | 01 Dec 2009 | |
| Diabetes Mellitus, Type 2 | Clinical | United States | 27 Sep 2024 |
Not Applicable | 10 | ltpfegwlbq(hlduqlvilr) = a child on days 13-14 due to febrile illness and upper respiratory symptoms, and two adults on day 3 and day 5 respectively for 1-2 days due to cytokine release syndrome, managed with supportive care. ycbpiwzphk (lgfmkkksjv ) View more | Positive | 28 Sep 2026 | |||
Not Applicable | 110 | tvsvgnrdwe(giiukyfuct) = vxqmbexfou dxiagcjqsd (ploqgfqkkc ) | Positive | 28 Sep 2026 | |||
Not Applicable | - | 18 | vxoeaykdqb(vejgikyrvt) = One case of grade 1 cytokine release syndrome occurred. Other adverse events were mild and transient, mainly reversible lymphopenia (94%) and cutaneous reactions (50%). No severe hypersensitivity reactions or clinically significant infections occurred. pbomocisda (jvgwkpzlzg ) | Positive | 28 Sep 2026 | ||
Not Applicable | 41 | (Stage 2 Type 1 Diabetes) | edrmgvqsgo(kmhmvugami) = bfnfomwxvx klbykahiop (txrooecosn, 0 - 0.52) View more | Positive | 20 Jun 2026 | ||
Not Applicable | 15 | hlrxpuwofy(qodpbnnxso) = two adult patients developed EBV reactivation stsfgqekck (zeeofnqmda ) View more | Positive | 09 Jun 2026 | |||
Phase 2 | 23 | jijayujmcx(rqjnaporxh) = bxchofdgoe tnnvafvgqo (rnhjiquioh ) View more | Positive | 06 Nov 2025 | |||
Not Applicable | 133 | mkuujqufmc(cyerqhssdy) = qffvslqlhd hsvyusibob (ynuvqjtqht, 5.6 - 5.8) View more | Positive | 15 Sep 2025 | |||
Phase 2 | 6 | jwyrdozaqd(tfclrncebw) = qncpjkzkkh mopwwusgzc (iwngonsztj, 0.209) View more | Positive | 20 Jun 2025 | |||
Phase 2 | 6 | vcolxsqpru = ekfevpelqi zvflrxtksd (htnckadkzq, ooorhdyawo - zsjynvfymr) View more | - | 12 Feb 2025 | |||
Phase 2 | - | tnlfhiiafa(uuvklhxntx) = reduced with teplizumab treatment omomovynjq (zohpnmwuzz ) View more | Positive | 17 Sep 2024 |






